ALS2CL

Across TCGA pan-cancer cohorts, ALS2CL mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ALS2CL’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ALS2CL mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ALS2CL is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, LSCC, and LUAD are the cancer types where ALS2CL tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ALS2CL mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−0.748	<.001	11	view →
LSCC	Female	All	−0.863	<.001	9	view →
LUAD	Female	III,IV	−0.762	<.001	9	view →
CCRCC	All	III,IV	−0.524	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ALS2CL–HNSC

Open the HNSC breakdown →